Physiomics plc (AIM: PYC) has secured a new £119,000 contract for drug development modelling while exploring additional commercial opportunities for its personalised dosing technology, including potential expansion into the US
Avacta to present cancer trial survival data and AVA6103 study design at ESMO 2026
Avacta Therapeutics (AIM: AVCT) will present updated clinical data from its Faridoxorubicin (AVA6000) cancer programme and details of its AVA6103 trial at the European Society for Medical Oncology (ESMO) Congress
Physiomics Revenue Hits Record £1.06m as Contract Pipeline Reaches New High
Physiomics plc (AIM: PYC) reported its highest annual income since incorporation, with revenue and grant income rising 26.5% to £1.06 million in the year ended 30 June 2026.
Genedrive Highlights NIHR Case Study Showing Potential £5m Annual NHS Savings
Genedrive plc (AIM: GDR) has highlighted a new case study published by the National Institute for Health and Care Research examining the development, clinical validation and adoption of its Genedrive
MedPal AI Says No Equity Raise Planned as Orders Hit Record and £8m Facility Talks Advance
MedPal AI plc (AIM: MPAL; FRA: Z1N) has issued a trading and financing update following sharp movements in its share price and trading volumes.
MedPal AI September Revenue Hits £3.2m as Annualised Run Rate Tops £38m
MedPal AI plc (AIM: MPAL; FRA: Z1N) reported another sharp increase in trading during September, with Group revenue reaching £3.2 million.
Avacta Therapeutics Raises £12.5m as Trading Resumes After Capital Access Window
Avacta Therapeutics (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share.
Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027
Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.
Physiomics, Can Contract Momentum Become Sustainable Growth?
Physiomics Plc (AIM: PYC) has started turning a commercial reset into a run of new contract awards. After shareholder-driven board changes in April, the company carried out a strategic and
Avacta Opens Capital Access Window Ahead of Equity Fundraise
Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.
Abingdon Health Official opening of manufacturing hub in the US
Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tech, announces the official opening yesterday of its
Avacta Group Further Demonstration of Potential of AVA6103
Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic